CKD is developing non-hydroxamic acid (NHA)-based histone deacetylase 6 (HDAC6) inhibitors for non-oncology indications. CKD’s NHA inhibitors address the limitations of hydroxamic acid (HA ...

DelveInsight’s, “HDAC Inhibitor Pipeline Insight” report provides comprehensive insights about 40+ companies and 50+ pipeline ...

Augustine Therapeutics NV has synthesized new heteroaryl-amine compounds acting as histone deacetylase 6 (HDAC6) inhibitors and thus reported to be useful for the treatment of inflammation, autoimmune ...

Augustine Therapeutics appoints Gerhard Koenigas Chief Executive Officer as Company Prepares to Enter the ClinicIndustry veteran Gerhard Koenig, ...

a small molecule HDAC6 inhibitor intended for heart failure with preserved ejection fraction (HFpEF), and multiple early-stage programs in preclinical development. For more information ...

Best-in-class highly selective HDAC6 inhibitor pioneer for disease-modifying treatment of neuromuscular, neurodegenerative and cardiometabolic diseases poised to enter the clinic LEUVEN ...

Industry veteran Gerhard Koenig, PhD, current Executive Chairman, appointed as CEO Best-in-class highly selective HDAC6 inhibitor pioneer for disease-modifying treatment of neuromuscular, ...

Best-in-class highly selective HDAC6 inhibitor pioneer for disease-modifying treatment of neuromuscular, neurodegenerative and cardiometabolic diseases poised to enter the clinic LEUVEN, Belgium – ...